Next Article in Journal
3D Analysis of HCMV Induced-Nuclear Membrane Structures by FIB/SEM Tomography: Insight into an Unprecedented Membrane Morphology
Next Article in Special Issue
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications
Previous Article in Journal
Low Proviral Load is Associated with Indeterminate Western Blot Patterns in Human T-Cell Lymphotropic Virus Type 1 Infected Individuals: Could Punctual Mutations be Related?
Previous Article in Special Issue
HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy
Article Menu

Export Article

Open AccessReview
Viruses 2015, 7(11), 5659-5685; doi:10.3390/v7112898

Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection

1
Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France
2
Université de Strasbourg, 67000 Strasbourg, France
3
Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
*
Author to whom correspondence should be addressed.
Academic Editor: Eric O. Freed
Received: 25 September 2015 / Revised: 25 September 2015 / Accepted: 19 October 2015 / Published: 2 November 2015
(This article belongs to the Special Issue HCV Drug Resistance)
View Full-Text   |   Download PDF [1478 KB, uploaded 2 November 2015]   |  

Abstract

Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC) which are leading indications of liver transplantation (LT). To date, there is no vaccine to prevent HCV infection and LT is invariably followed by infection of the liver graft. Within the past years, direct-acting antivirals (DAAs) have had a major impact on the management of chronic hepatitis C, which has become a curable disease in the majority of DAA-treated patients. In contrast to DAAs that target viral proteins, host-targeting agents (HTAs) interfere with cellular factors involved in the viral life cycle. By acting through a complementary mechanism of action and by exhibiting a generally higher barrier to resistance, HTAs offer a prospective option to prevent and treat viral resistance. Indeed, given their complementary mechanism of action, HTAs and DAAs can act in a synergistic manner to reduce viral loads. This review summarizes the different classes of HTAs against HCV infection that are in preclinical or clinical development and highlights their potential to prevent HCV infection, e.g., following LT, and to tailor combination treatments to cure chronic HCV infection. View Full-Text
Keywords: hepatitis C virus; host-targeting agent; direct-acting antiviral; viral resistance hepatitis C virus; host-targeting agent; direct-acting antiviral; viral resistance
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zeisel, M.B.; Crouchet, E.; Baumert, T.F.; Schuster, C. Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses 2015, 7, 5659-5685.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top